journal article·2024-11Open access

Inhalable Dry Powders for Lung mRNA Delivery

Akiva Gordon, Bowen Li, Jacob Witten, Hong Nguyen, Daniel G. Anderson

Advanced Healthcare Materials· Volume 13· Issue 29

Abstract

Abstract Despite great promise, application of mRNA therapeutics in the lung has proven challenging. Many groups have reported success instilling liquid mRNA formulations in animal models, but direct intratracheal administration of large liquid quantities to the human lung presents significant safety and distribution concerns. To accomplish safe and effective mRNA delivery to the lung, formulations must be prepared for dosing via inhalation. An inhaled mRNA delivery system for the lung must be both robust enough to survive inhalation conditions and potent enough to deliver mRNA upon reaching the lung. In this work dry powder lipid nanoparticle formulations are developed, using spray‐freeze‐drying, to produce stable, biologically active, inhalable dry powders for mRNA delivery. The final powders have suitable aerosolization properties, with mean mass aerodynamic diameter (MMAD) of 3–4 microns, and fine particle fraction (FPF) ≈40%, allowing for efficient mRNA delivery to the deep lung following inhalation. Importantly, the formulations developed here are suitable for use with different ionizable lipids. Four different ionizable lipid‐based formulations are evaluated as powders, and all exhibit in vivo pulmonary mRNA delivery equal to that of instilled liquid formulations. These results lay promising groundwork for the eventual development of an inhalable mRNA dry powder therapeutic.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Inhalation and Respiratory Drug Delivery · RNA Interference and Gene Delivery · Neonatal Respiratory Health Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

David H Koch Institute for Integrative Cancer Research Massachusetts Institute of Technology Cambridge MA 02139 USA

Department of Chemical Engineering Massachusetts Institute of Technology Cambridge MA 02139 USA

Leslie Dan Faculty of Pharmacy University of Toronto Toronto Ontario Canada

Institute of Biomedical Engineering University of Toronto Toronto Ontario Canada

Department of Chemistry University of Toronto Toronto Ontario Canada

Department of Biological Engineering Massachusetts Institute of Technology Cambridge MA 02139 USA

Department of Anesthesiology Boston Children's Hospital Boston MA 02115 USA

Department of Statistics University of Michigan Ann Arbor USA

Harvard and MIT Division of Health Science and Technology Massachusetts Institute of Technology Cambridge MA 02139 USA

Funding

National Institutes of Health · Cystic Fibrosis Foundation · Alpha-1 Foundation · Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology · Sanofi · National Cancer Institute

References (57)

Show source-provided references
1. 10.1056/NEJMoa203457710.1056/NEJMoa2034577 ↗
2. 10.1056/NEJMoa203538910.1056/NEJMoa2035389 ↗
3. 10.1038/s41541-020-0159-810.1038/s41541-020-0159-8 ↗
4. 10.1126/science.ade696710.1126/science.ade6967 ↗
5. 10.1021/acs.nanolett.3c0030410.1021/acs.nanolett.3c00304 ↗
6. 10.1021/acsami.2c2168310.1021/acsami.2c21683 ↗
7. 10.1126/SCIADV.ABJ690110.1126/SCIADV.ABJ6901 ↗
8. 10.1002/adma.20200661910.1002/adma.202006619 ↗
9. 10.1038/s41587-023-01679-x10.1038/s41587-023-01679-x ↗
10. 10.1038/s41587-023-01824-610.1038/s41587-023-01824-6 ↗
11. 10.1016/S0140-6736(16)00576-610.1016/S0140-6736(16)00576-6 ↗
12. Stoller J. K. · GeneReviews · 2023
13. 10.1016/S2213-2600(19)30374-110.1016/S2213-2600(19)30374-1 ↗
14. 10.1038/s41565-020-0669-610.1038/s41565-020-0669-6 ↗
15. 10.1038/s41467-023-42948-210.1038/s41467-023-42948-2 ↗
16. 10.1038/s41551-021-00786-x10.1038/s41551-021-00786-x ↗
17. 10.1021/acsnano.2c0564710.1021/acsnano.2c05647 ↗
18. 10.1038/s41565-023-01548-310.1038/s41565-023-01548-3 ↗
19. 10.3390/vaccines909103310.3390/vaccines9091033 ↗
20. 10.1186/s40545-022-00411-510.1186/s40545-022-00411-5 ↗
21. 10.1016/j.addr.2021.02.01710.1016/j.addr.2021.02.017 ↗
22. 10.1080/17425247.2020.170264310.1080/17425247.2020.1702643 ↗
23. 10.1183/09031936.94.0712218510.1183/09031936.94.07122185 ↗
24. 10.1016/j.ejpb.2015.07.01610.1016/j.ejpb.2015.07.016 ↗
25. 10.1016/j.jconrel.2009.10.01010.1016/j.jconrel.2009.10.010 ↗
26. 10.1016/j.jconrel.2011.08.01110.1016/j.jconrel.2011.08.011 ↗
27. 10.1016/j.ijpharm.2021.12021510.1016/j.ijpharm.2021.120215 ↗
28. V.Patel D.Bardoliwala R.Lalani S.Patil S.Ghosh A.Javia A.Misra 2021 12 651.10.4155/tde-2020-0117 ↗
29. 10.1248/bpb.b13-0016710.1248/bpb.b13-00167 ↗
30. 10.1021/mp500745v10.1021/mp500745v ↗
31. 10.1007/s11095-015-1747-610.1007/s11095-015-1747-6 ↗
32. 10.1016/j.ijpharm.2017.05.04610.1016/j.ijpharm.2017.05.046 ↗
33. 10.1016/j.ijpharm.2017.07.01310.1016/j.ijpharm.2017.07.013 ↗
34. 10.1016/j.ejpb.2017.08.00110.1016/j.ejpb.2017.08.001 ↗
35. 10.1016/j.jconrel.2018.04.00310.1016/j.jconrel.2018.04.003 ↗
36. 10.1016/j.omtn.2018.07.00910.1016/j.omtn.2018.07.009 ↗
37. 10.1016/j.ajps.2017.10.00210.1016/j.ajps.2017.10.002 ↗
38. 10.1016/j.ijpharm.2018.09.04510.1016/j.ijpharm.2018.09.045 ↗
39. 10.1016/j.ijpharm.2019.05.01910.1016/j.ijpharm.2019.05.019 ↗
40. 10.1016/j.xphs.2019.03.02910.1016/j.xphs.2019.03.029 ↗
41. 10.1007/s11095-019-2663-y10.1007/s11095-019-2663-y ↗
42. 10.1016/j.ijpharm.2019.11881810.1016/j.ijpharm.2019.118818 ↗
43. 10.1002/wnan.163410.1002/wnan.1634 ↗
44. 10.1016/j.jconrel.2019.10.02610.1016/j.jconrel.2019.10.026 ↗
45. 10.1016/j.matt.2022.06.01210.1016/j.matt.2022.06.012 ↗
46. 10.1007/s13346-023-01402-y10.1007/s13346-023-01402-y ↗
47. 10.1016/j.jconrel.2023.09.03110.1016/j.jconrel.2023.09.031 ↗
48. 10.1016/j.omtn.2017.11.00510.1016/j.omtn.2017.11.005 ↗
49. 10.1023/A:101891020042010.1023/A:1018910200420 ↗
50. 10.2147/IJN.S12306210.2147/IJN.S123062 ↗
51. 10.1016/0021-8502(96)00046-810.1016/0021-8502(96)00046-8 ↗
52. 10.1021/acs.nanolett.5b0249710.1021/acs.nanolett.5b02497 ↗
53. 10.1002/anie.20120326310.1002/anie.201203263 ↗
54. 10.1016/j.jcf.2023.04.00810.1016/j.jcf.2023.04.008 ↗
55. 10.1038/nbt.160210.1038/nbt.1602 ↗
56. 10.1038/mt.2013.12410.1038/mt.2013.124 ↗
57. 10.1021/ja301621z10.1021/ja301621z ↗